Phase IV trials have a retention problem that Phase III rarely faces: patients who are already stable, already treated, and not obviously getting anything new from showing up. A Fortrea case study published this month describes how a heart failure Phase IV study addressed that exact dynamic, using digital health tools, electronic patient-reported outcomes (ePRO), and remote monitoring to hold enrollment together when participants saw little personal upside in continuing.
The “low benefit” perception is a specific and underappreciated dropout driver in post-marketing research. Patients in Phase IV heart failure studies are typically on stable, optimized regimens, and the study is not offering an experimental drug that might help them. The case study frames this as a recruitment and retention challenge requiring deliberate design choices, not just protocol amendments after the fact. Remote monitoring and ePRO reduced the burden of site visits, which is the most direct lever available: fewer trips to the clinic removes one of the clearest reasons a stable, working-age or elderly heart failure patient drops out.
The timing connects to a real regulatory shift. The FDA’s 2024 final guidance on decentralized clinical trial elements gave sponsors clearer footing to build remote components into study design from the start, rather than treating them as contingency workarounds. For Phase IV, where the population is broad and community-based rather than concentrated at academic medical centers, that guidance matters more than in earlier-phase work. Heart failure patients in particular are often managing comorbidities and mobility limitations that make frequent site attendance unrealistic.
The case study does not publish retention rates or dropout figures, which limits how far the results can be evaluated. What it does show is the operational logic: digital tools were chosen to address a known psychological and logistical barrier, not applied generically. The question worth tracking for anyone designing a similar study is whether ePRO completion rates held steady across the trial’s duration or showed the familiar mid-study decay that remote data collection often surfaces once novelty wears off.
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
